The bankruptcy court’s approval of this sale provides reason for cautious optimism,” said Rhode Island Attorney General Peter ...

GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.

BD announced it would split from its biosciences and diagnostics unit, while Zimmer Biomet updated investors on its $1.1 ...

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

We combine progressive healthcare education and patient care with world-class research and outstanding teaching facilities in order to help you to become the very best doctor you can be. But don't ...

Jefferies analyst reiterated a Buy rating for Globus Medical (NYSE:GMED), with a steady price target of $105.00, following the company's announcement of its plans to acquire Nevro Corp . (NYSE:NVRO), ...

In a report released today, David Saxon from Needham maintained a Hold rating on Globus Medical (GMED – Research Report). The company’s shares ...